Novartis AG ADR
NVS: XNYS (USA)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
$169.00 | Bzvbn | Hwzsxjn |
Novartis Earnings: Better-Than-Expected Broad-Based Results Support Fair Value Estimate Increase
Novartis reported first-quarter results ahead of our expectations, and we've increased our fair value estimate to $105 (CHF 96 local share class) from $98 (CHF 88). Strong top-line growth combined with core margin expansion sets up the company well to meet management’s raised 2024 guidance of low-double-digit to midteens earnings growth.